Hyperglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Insulin Treatment for Blood Glucose Control in Adult Critically Ill Patients with Stress Hyperglycemia https://clinicaltrials.eu/trial/study-on-the-effect-of-insulin-human-for-blood-sugar-control-in-critically-ill-adult-patients-with-stress-hyperglycemia/ Wed, 29 Apr 2026 14:58:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-insulin-human-for-blood-sugar-control-in-critically-ill-adult-patients-with-stress-hyperglycemia/ This study focuses on managing hyperglycemia (high blood sugar) in critically ill patients who are being treated in the intensive care unit (ICU). The condition being studied is known as stress hyperglycemia, which often occurs in severely ill patients even if they have not previously had diabetes. The treatment being tested involves the use of human insulin to strictly control blood sugar levels within normal fasting ranges.

The purpose of this research is to determine if keeping blood sugar levels tightly controlled within normal ranges using a specific dosing plan (called the Leuven algorithm) leads to better outcomes compared to allowing higher blood sugar levels in critically ill adult patients. During the study, patients will receive insulin through an intravenous line, with doses adjusted according to their blood sugar measurements.

The study will monitor how the treatment affects patients’ recovery during their ICU stay. This includes tracking how long patients need intensive care support, checking for complications, and following their overall progress. The maximum daily dose of insulin that may be given is 1,200 international units, and patients may receive treatment for up to 12 months if needed.

]]> Study on the Safety and Effectiveness of Oral Semaglutide for Patients with High Blood Sugar After Kidney Transplantation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oral-semaglutide-for-patients-with-high-blood-sugar-after-kidney-transplantation/ Wed, 29 Apr 2026 14:23:54 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oral-semaglutide-for-patients-with-high-blood-sugar-after-kidney-transplantation/ This clinical trial is focused on studying the safety and effectiveness of a medication called oral semaglutide, also known as Rybelsus, in patients who experience high blood sugar levels, or hyperglycemia, after receiving a kidney transplant. The study aims to determine if oral semaglutide, when compared to a placebo, can effectively manage blood sugar levels in these patients. The medication is taken in the form of tablets and is used alongside the standard care that patients are already receiving.

Participants in the study will be given either oral semaglutide or a placebo, and their blood sugar levels will be monitored over a period of time. The study will assess how well the medication helps in maintaining blood sugar within a target range and will also look at other health indicators such as body weight, blood pressure, and kidney function. The trial will also monitor any side effects or adverse events that may occur during the treatment period.

The study is expected to continue until 2026, and it will provide valuable information on the potential benefits and risks of using oral semaglutide in managing hyperglycemia in patients who have undergone a kidney transplant. This research could help improve treatment options for these patients in the future.

]]> Study on the Safety and Effectiveness of Oral Semaglutide for Patients with High Blood Sugar After Kidney Transplantation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oral-semaglutide-for-patients-with-high-blood-sugar-after-kidney-transplantation-2/ Wed, 29 Apr 2026 14:23:31 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-oral-semaglutide-for-patients-with-high-blood-sugar-after-kidney-transplantation-2/ This clinical trial is focused on studying the safety and effectiveness of a medication called oral semaglutide, which is marketed under the name Rybelsus. The study is specifically for patients who experience high blood sugar levels, known as hyperglycemia, after undergoing a kidney transplant. The trial will compare the effects of Rybelsus with a placebo, both used alongside the usual care that patients receive.

The main goal of the study is to determine if Rybelsus is as effective as the placebo in managing blood sugar levels in these patients. Participants in the study will take either Rybelsus or a placebo in the form of tablets. The study will last for a period of 14 days, during which the participants’ blood sugar levels will be closely monitored. This will help researchers understand how well the medication works in controlling blood sugar levels in patients who have had a kidney transplant.

Throughout the study, various health indicators will be observed, such as body weight, blood pressure, and kidney function. The study will also track any side effects or adverse events that participants may experience. The trial is expected to continue until September 2026, providing valuable insights into the management of high blood sugar in patients after kidney transplantation.

]]>